US Patent 9815817 Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
Patent 9815817 was granted and assigned to FORMA Therapeutics on November, 2017 by the United States Patent and Trademark Office.
All edits
Edits on 7 Aug, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
0
Edits on 24 Apr, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 6 Dec, 2023
Golden AI
Edits made to:
Article (+217 characters)
Article
Patent abstract
The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula:
Edits on 30 Sep, 2023
Golden AI
Edits made to:
Infobox (+10 properties)
Infobox
Patent Inventor Names
Ann-Marie Campbell0
Anna Ericsson0
David R. Lancia, Jr.0
Gary Gustafson0
Jian Lin0
Justin Andrew Caravella0
R Bruce Diebold0
Susan Ashwell0
Wei Lu0
Zhongguo Wang0
Edits on 14 Jul, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 09815817 Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors US Patent 9815817 Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
Infobox
Patent Number
09815817
Patent Number
9815817
Edits on 15 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 09815817 Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
09815817
Date of patent
November 14, 2017
Patent application number
14858165
Date Filed
September 18, 2015
Patent primary examiner
Find more entities like US Patent 9815817 Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
